Last reviewed · How we verify
Preservative-Free Tafluprost or vehicle
Preservative-Free Tafluprost or vehicle is a Prostaglandin analogue Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Glaucoma. Also known as: MK-2452.
Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.
Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow. Used for Glaucoma.
At a glance
| Generic name | Preservative-Free Tafluprost or vehicle |
|---|---|
| Also known as | MK-2452 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Prostaglandin analogue |
| Target | Prostaglandin F2α receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Tafluprost works by mimicking the action of prostaglandin F2α, a naturally occurring substance in the body that helps to reduce intraocular pressure. This is achieved by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby reducing the pressure in the eye. This mechanism of action is similar to other prostaglandin analogues used to treat glaucoma.
Approved indications
- Glaucoma
Common side effects
- Eyelid skin darkening
- Periorbital fat atrophy
- Eyelash growth
- Itching
- Redness of the eye
- Dry eye
- Eye irritation
- Headache
- Dizziness
- Nausea
Key clinical trials
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
- Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preservative-Free Tafluprost or vehicle CI brief — competitive landscape report
- Preservative-Free Tafluprost or vehicle updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Preservative-Free Tafluprost or vehicle
What is Preservative-Free Tafluprost or vehicle?
How does Preservative-Free Tafluprost or vehicle work?
What is Preservative-Free Tafluprost or vehicle used for?
Who makes Preservative-Free Tafluprost or vehicle?
Is Preservative-Free Tafluprost or vehicle also known as anything else?
What drug class is Preservative-Free Tafluprost or vehicle in?
What development phase is Preservative-Free Tafluprost or vehicle in?
What are the side effects of Preservative-Free Tafluprost or vehicle?
What does Preservative-Free Tafluprost or vehicle target?
Related
- Drug class: All Prostaglandin analogue drugs
- Target: All drugs targeting Prostaglandin F2α receptor
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Glaucoma
- Also known as: MK-2452
- Compare: Preservative-Free Tafluprost or vehicle vs similar drugs
- Pricing: Preservative-Free Tafluprost or vehicle cost, discount & access